SAM
BBIO icon

SEB Asset Management’s BridgeBio Pharma BBIO Stock Holding History

SEB Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.55M Sell
128,287
-107,526
-46% -$7.53M 0.04% 347
2026
Q1 		$17.5M Buy
+235,813
New +$17.1M 0.07% 221

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

SEB Asset Management's BBIO Position: Q2 2026 in Review

SEB Asset Management reduced its BridgeBio Pharma (BBIO) stake by 46% in Q2 2026, selling an estimated $7.53M and leaving 128,287 shares worth $9.55M. The position accounts for 0.04% of the portfolio, ranked #347.

SEB Asset Management first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $17.5M in Q1 2026. 439 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • SEB Asset Management held 128,287 shares of BridgeBio Pharma worth $9.55M as of Q2 2026.
  • SEB Asset Management sold 107,526 BridgeBio Pharma shares in Q2 2026, an estimated $7.53M.
  • BridgeBio Pharma made up 0.04% of SEB Asset Management's portfolio in Q2 2026, its #347 holding.
  • SEB Asset Management first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • SEB Asset Management's BridgeBio Pharma position peaked at $17.5M in Q1 2026.
  • 439 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.